Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 86

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 86
---
 reporting period, between April and July 2025, following comments received from the Securities and Exchange Commission, NLS filed several amendments to a registration statement on Form F -4which includes, inter alia, a description of the Company’s activities, its updated annual financial statements as of December 31, 2024 and several clarifications made to the Merger Agreement based on the terms as agreed between the parties within the framework of the merger transaction, as approved by the Company’s shareholders’ meeting. C.On July 17, 2025, following the Company’s reports regarding a joint development with ITOLERANCE Ltd. (the “Joint Development”) pursuant to which the Company is entitled to a grant in a total amount of $1 million from Bi -NationalIndustrial Research and Development Foundation (“BIRD -F”) and the Company’s reports on previous payment approvals from the grant, the Company announced that on July 16, 2025, the BIRD -Fapproved an additional payment for the Joint Development from the grant, amounting to approximately $166 thousand and in aggregation since the commencing of the project approximately $833 thousand, for the progress of the development at this stage (the “Approval of the additional payment”). The approval of the additional payment was received following the Company’s successful PRE -INDmeeting with the U.S. Food and Drug Administration (FDA) in February 2025. Management believes the decision by the BIRD -Fto approve the additional payment is recognition of the scientific and business achievements of the Company and ITOLERANCE, which are collaborating on the continued steps of Joint Development as mentioned above. D.On August 13, 2025, Mr. Julien Ruggieri, a significant shareholder of the Company, exercised 140,066 warrants from a 2023 agreement, into the same number of ordinary shares of the Company, as part of the convertible loan transaction, in consideration for a total of $276 thousand. E.On August 29, 2025, the Company’s Board of Directors approved the amendment to the Merger Agreement to extend the deadline for completion of the merger transaction by up to 60 days until October 31, 2025. - - - - - - - - - - - - - - - - - - - - - - Annex B-13 PART II
INFORMATION NOT REQUIRED IN PROSPECTUS Item 20. Indemnification Under Swiss law, a corporation may indemnify its directors or officers against losses and expenses (except for such losses and